

# *PRKCH* 1425G/A Polymorphism Predicts Recurrence of Ischemic Stroke in a Chinese Population

Zhizhong Zhang · Gelin Xu · Wusheng Zhu ·  
Liping Cao · Bernard Yan · Xinfeng Liu

Received: 30 July 2014 / Accepted: 24 October 2014 / Published online: 5 November 2014  
© Springer Science+Business Media New York 2014

**Abstract** A recent genome-wide association study (GWAS) identified a nonsynonymous SNP (1425G/A) in *PRKCH* which was associated with increased risk of ischemic stroke. The purpose of this study was to examine whether this functional polymorphism is associated with stroke onset and prognosis in a Chinese population. We genotyped *PRKCH* 1425G/A using Improved Multiple Ligase Detection Reaction in 919 patients with ischemic stroke. Analyses of genotype association with onset and prognosis outcomes were assessed by the Kaplan-Meier method, the log-rank test, and the Cox proportional hazards models. *PRKCH* 1425G/A was not associated with age of stroke onset ( $P=0.323$ ). However, this functional polymorphism was significantly associated with risk of stroke recurrence in recessive models (hazard ratio [HR]=2.23; 95 % confidential interval [CI], 1.06 to 4.68;  $P=0.014$ ), and this effect was more predominant among smokers (HR=3.67; 95 % CI, 1.47–9.18;  $P=0.005$ ). Moreover, the variant genotypes of *PRKCH* 1425G/A are an independent prognostic factor for ischemic stroke in the final multivariate Cox regression model. Our findings show that *PRKCH* 1425G/A may be a useful biomarker for predicting the recurrence of ischemic stroke.

**Keywords** *PRKCH* · Polymorphism · Stroke · Recurrence

**Electronic supplementary material** The online version of this article (doi:10.1007/s12035-014-8964-6) contains supplementary material, which is available to authorized users.

Z. Zhang · G. Xu · W. Zhu · L. Cao · X. Liu (✉)  
Department of Neurology, Jinling Hospital, Nanjing University  
School of Medicine, 305# East Zhongshan Road,  
Nanjing 210002, Jiangsu Province, China  
e-mail: xfliu2@vip.163.com

B. Yan  
Melbourne Brain Centre, Royal Melbourne Hospital, University of  
Melbourne, Melbourne, Australia

## Abbreviations


HR Hazard ratio  
CI Confidence interval  
GWAS Genome-wide association study

## Introduction

Stroke is a major cause of death and long-term disability worldwide, leading to serious public health problems [1]. Primary prevention of stroke is therefore an important medical and social issue. Reports involving twin and family studies have shown that genetics play crucial roles in the development of ischemic stroke, and there has been substantial research evaluating specific genetic risk factors for ischemic stroke [2, 3].

To date, genome-wide association study (GWAS) has emerged as a new promising tool to identify potential susceptibility variants with moderate genetic risk on many complex diseases [4]. In 2007, *PRKCH* was identified as a novel candidate gene for ischemic stroke using genome-wide SNP analysis, and the nonsynonymous SNP (1425G/A) in *PRKCH* was reported to be associated with the risk of ischemic stroke in a Japanese population-based sample [5]. This SNP is located in the linkage disequilibrium block in the *PRKCH* gene (Fig. 1) that encodes PKC $\eta$ , a molecule that plays important roles in the process of atherosclerosis [5]. Subsequently, the study was followed by many studies in an attempt to replicate this finding in other populations [6–8]. Nevertheless, most of these studies focused on stroke susceptibility. The roles of *PRKCH* 1425G/A polymorphism in stroke onset and prognosis are still largely unknown. Therefore, we hypothesized that the *PRKCH* 1425G/A polymorphism was associated with

**Fig. 1** Linkage disequilibrium (LD) pattern of SNPs on chromosome 14q22–q23 based on the HapMap reference sample (Han Chinese in Beijing, China) and NCBI36/hg18 genome build. The LD structure indicates the pairwise calculation of  $D'$  for each possible combination of SNPs



onset and prognosis of ischemic stroke and conducted a cohort study to test this hypothesis in a Chinese population.

## Methods

### Study Subjects

Our study was approved by the Institutional Review Board of Jinling Hospital (Nanjing, China). A total of 919 ischemic stroke patients were prospectively recruited between December 2009 and May 2011 from the Nanjing Stroke Registry Program (NSRP) [9]. All ischemic stroke patients suffered a focal neurologic deficit lasting >24 h and were confirmed by computed tomography (CT) or magnetic resonance imaging (MRI). The detailed diagnosis of ischemic stroke patients was described previously [10]. Those who smoked daily for >1 year were defined as smokers. Patients were prospectively followed up every 3 months after enrollment via telephone interview or clinical visit until the study endpoint (recurrent stroke) or the latest follow-up time period (November 2013). The median follow-up time was 25.8 months. During the


follow-up period, 64 patients were lost to follow-up and 75 had recurrent stroke. Those lost to follow-up were considered as censored data.

### Genotyping

Genomic DNA was extracted according to standard procedures. Genotyping was conducted by the Improved Multiple Ligase Detection Reaction (iMLDR) [11], with technical support from the Center for Human Genetics Research, Shanghai Genesky Biotechnology Company. About 5 % of the samples were randomly selected for confirmation, and the results were 100 % concordant.

### Statistical Analysis

One-way ANOVA was adopted to compare the average age at stroke onset. Survival time was calculated from the date of stroke diagnosis to the date of study endpoint or the time of last follow-up. Log-rank test was used to compare the different survival times according to demographic, clinical information, and genotypes. Univariate and multivariate Cox regression models were performed to estimate the crude hazard



**Fig. 2** Correlation between the *PRKCH* 1425G/A and age at onset. **a** A box plot of age at onset between three groups of patients with the wild type (GG), heterozygote (GA), or mutant homozygote (AA). • indicates outliers. **b**

Cumulative incidence curve of the three groups of patients with the wild type (GG), heterozygote (GA), or mutant homozygote (AA)

ratios (HRs) or adjusted HRs and their 95 % confidential intervals (CIs). All tests were two sided by using the SAS (version 9.1.3) and STATA (version 12.0).

## Results

### Genotyping Results and Their Associations with Stroke Onset

We first evaluated if *PRKCH* 1425G/A affected the age of disease onset. The mean age of onset for the GG, GA, and AA groups were  $61.33 \pm 12.65$ ,  $60.28 \pm 13.16$ , and  $62.89 \pm 11.70$ , respectively ( $P=0.323$ ) (Fig. 2). The result indicated that the *PRKCH* 1425G/A SNP was not associated with age of stroke onset.

### Genotyping Results and Their Association with Recurrence

The final population for prognosis of this study consisted of 855 ischemic stroke patients. The demographic and clinical information is shown in Table 1. The median age was 62 years, including 602 males (70.4 %) and 253 females (29.6 %). Age and hypertension were significantly associated with recurrence time (log-rank  $P < 0.05$ ). As shown in Table 2, Cox regression analyses were used to assess the association of *PRKCH* 1425G/A with ischemic stroke recurrence in different genetic models. As a result, *PRKCH* 1425G/A was significantly associated with risk of recurrence in a recessive model (log-rank  $P=0.014$ , Fig. 3). Cox regression analyses indicated that the AA variant genotype had a 123 % significant increase recurrence risk (HR=2.23; 95 % CI, 1.06–4.68), compared to the GG/GA genotypes. In the subgroup analyses by stroke subtype, the variant AA genotype was associated with a higher risk of recurrence for both large-artery atherosclerosis (LAA) and small-vessel disease (SVD), which was not statistically significant ( $P=0.218$  and  $0.095$ , respectively).

### Stratification Analyses

Cox proportional hazard regression analysis showed that *PRKCH* 1425 AA was a significantly unfavorable prognostic factor for ischemic stroke (adjusted HR, 2.23, 95 % CI, 1.06–4.68;  $P=0.014$ ; Table 2). In Table 3, age, sex, hypertension, and smoking all seem to be associated with an increased risk for recurrence of ischemic stroke in the AA genotype. Further stratification analysis indicated that this increased risk was more pronounced among smokers (HR=3.67; 95 % CI, 1.47–9.18;  $P=0.005$ ; Table 3). Moreover, multivariate cox

**Table 1** Patient characteristics and clinical features

Variables	Patients $N=855$ (%)	Recurrence $N=75$	Log-rank $P$
Age (years)			0.026
$\leq 60$	381 (44.6)	25	
$> 60$	474 (55.4)	50	
Sex			0.122
Male	602 (70.4)	59	
Female	253 (29.6)	16	
Hypertension			0.026
No	307 (35.9)	18	
Yes	548 (64.1)	57	
Diabetes			0.275
No	677 (79.2)	56	
Yes	178 (20.8)	19	
Smoking			0.567
No	530 (62.0)	43	
Yes	325 (38.0)	32	
TOAST			0.076
LAA	515 (60.2)	41	
SVD	250 (29.3)	26	
CE	30 (3.5)	5	
UND	60 (7.0)	3	

LAA large-artery atherosclerosis, SVD small-vessel disease, CE cardiac embolism, UND other determined and undetermined causes


**Table 2** Association between *PRKCH* 1425G/A and recurrence of ischemic stroke

Genetic models	Genotypes	All cases ( <i>n</i> =855)			
		Patients ( <i>n</i> )	Recurrence ( <i>n</i> )	Log-rank <i>P</i>	HR (95%CI) <sup>a</sup>
Codominant model	GG	502	49	0.008	1.00
	GA	309	18		0.60 (0.35–1.03)
	AA	44	8		1.91 (0.90–4.05)
Dominant model	GG	502	49	0.252	1.00
	GA/AA	353	26		0.76 (0.47–1.23)
Recessive model	GG/GA	811	67	0.014	1.00
	AA	44	8		2.23 (1.06–4.68)
		LAA ( <i>n</i> =515)			
		Patients ( <i>n</i> )	Recurrence ( <i>n</i> )	Log-rank <i>P</i>	HR (95%CI) <sup>a</sup>
Codominant model	GG	297	29	0.041	1.00
	GA	187	8		0.39 (0.18–0.85)
	AA	31	4		1.43 (0.49–4.12)
Dominant model	GG	297	29	0.075	1.00
	GA/AA	218	12		0.51 (0.26–1.01)
Recessive model	GG/GA	484	37	0.218	1.00
	AA	31	4		1.87 (0.66–5.36)
		SVD ( <i>n</i> =250)			
		Patients ( <i>n</i> )	Recurrence ( <i>n</i> )	Log-rank <i>P</i>	HR (95%CI) <sup>a</sup>
Codominant model	GG	147	15	0.241	1.00
	GA	91	8		1.17 (0.49–2.80)
	AA	12	3		2.10 (0.60–7.31)
Dominant model	GG	147	15	0.819	1.00
	GA/AA	103	11		1.34 (0.61–2.94)
Recessive model	GG/GA	238	23	0.095	1.00
	AA	12	3		2.00 (0.59–6.73)

<sup>a</sup> Adjusted for age, sex, hypertension, diabetes, and smoking

proportional hazard analysis also showed that the *PRKCH* 1425G/A is an independent prognostic marker for recurrence of ischemic stroke ( $P=0.033$ ; Table 4). Next, we evaluated whether there exist potential interaction between the *PRKCH* 1425G/A polymorphism and tobacco smoking on recurrence risk of ischemic stroke. As shown in Supplementary Table 1, compared with nonsmokers who carried the GG/GA genotype, smokers with the GG/GA genotype had a 1.002-fold (95 % CI, 0.613–1.638) increased recurrence risk of ischemic

stroke, and nonsmokers with the AA had a 1.308-fold (95 % CI, 0.316–5.410) increased recurrence risk of ischemic stroke, whereas smokers with AA genotype had the highest risk, with the HR being 3.436 (95 % CI, 1.457–8.102), which is threefold greater than the product of the HR for smokers with the GG/GA genotype and the HR for nonsmokers with AA genotype (Supplementary Table 1).



**Fig. 3** Kaplan-Meier survival curves for recurrence among ischemic stroke cases

## Discussion

In this cohort study, we investigated whether there is a correlation between the *PRKCH* 1425G/A polymorphism and onset and prognosis of ischemic stroke in a Chinese population. Our results indicated that this functional SNP was not associated with age of stroke onset. However, we found that *PRKCH* 1425G/A was significantly associated with risk of stroke recurrence, and this effect was more prominent among smokers. Moreover, the variant genotypes of *PRKCH* 1425G/A was an independent prognostic factor for ischemic

**Table 3** Stratified analysis of *PRKCH* 1425G/A genotypes associated with recurrence of ischemic stroke

Variable	Genotype (recurrence/patients)		HR (95%CI) <sup>a</sup>
	GG/GA	AA	
Total	67/811	8/44	2.23 (1.06–4.68)
Age (years)			
≤60	22/363	3/18	2.81 (0.82–9.60)
>60	45/448	5/26	2.00 (0.79–5.10)
Sex			
Male	51/565	8/37	2.62 (1.24–5.57)
Female	16/246	0/7	—
Hypertension			
No	17/294	1/13	1.24 (0.16–9.63)
Yes	50/517	7/31	2.48 (1.12–5.51)
Diabetes			
No	49/639	7/38	2.31 (1.04–5.14)
Yes	18/172	1/6	1.94 (0.25–15.04)
Smoking			
No	41/510	2/20	1.14 (0.27–4.73)
Yes	26/301	6/24	3.67 (1.47–9.18)

<sup>a</sup> Adjusted for age, sex, hypertension, diabetes, and smoking

stroke in the final multivariate Cox regression model. These findings showed that *PRKCH* 1425G/A may be a useful biomarker for predicting the recurrence of ischemic stroke.

PKC family mediates various signaling pathways and regulates multiple important cellular functions such as proliferation, differentiation, and apoptosis [5, 12]. PKC $\eta$ , encoded by *PRKCH*, is a serine-threonine kinase and is involved in the development and progression of atherosclerosis [5]. Recently, Kubo et al. reported that PKC $\eta$  was mainly expressed in vascular endothelial cells, and it plays crucial roles in the development of atherosclerotic diseases such as stroke [5]. The nonsynonymous SNP (1425G/A), which lies in exon 9 and within the ATP-binding site of PKC $\eta$ , causes enhancement of PKC activity, which may increase stroke risk.

**Table 4** Multivariate cox regression analysis for recurrence

Variables	$\beta$	SE	HR	95 % CI	P
Age	0.47	0.25	1.61	0.99–2.62	0.057
Sex	−0.46	0.30	0.63	0.35–1.14	0.127
Hypertension	0.47	0.28	1.60	0.93–2.74	0.091
Diabetes	0.30	0.27	1.35	0.79–2.31	0.267
Smoking	0.05	0.25	1.05	0.64–1.72	0.838
<i>PRKCH</i> 1425 (GG/GA vs. AA)	0.80	0.38	2.23	1.06–4.68	0.033

$\beta$  regression coefficient

In our study, smokers with the *PRKCH* 1425 AA genotype had the highest recurrent risk of ischemic stroke, suggesting that smoking may have a joint effect with *PRKCH* 1425G/A on recurrence of ischemic stroke. Smoking is known to be an important risk factor for ischemic stroke [13]. Tobacco smoke contains thousands of potentially harmful chemicals, some of which are known to promote atherosclerosis [14]. In addition, tobacco smoke causes vascular endothelial dysfunction with related alteration in hemostatic and inflammatory markers [15, 16]. Of note, it has been reported that smoking could also increase the concentration of fibrinogen and aggregability of platelet, reduce fibrinolytic activity, and cause polycythemia [17–20]. Thus, it is biologically plausible that smokers with the AA genotype had the highest recurrent risk for ischemic stroke.

The limitation of our study is its hospital-based design, leading to the possibility of selection bias. However, the genotype distributions in our study population were similar to that reported in published data for Chinese populations. For instance, the frequencies of the GG, GA, and AA genotypes among our southern Chinese subjects were 58.7, 36.1, and 5.2 %, respectively, compared with 56.0, 40.0, and 4.0 in northern Chinese populations in the study by Wu et al. [8]. However, the MAF of this SNP is relatively low in European and African populations. Thus, more evidence was needed from other populations to further investigate the association between the *PRKCH* 1425 G/A and recurrence of ischemic stroke. In addition, the number of patients is relatively small in some stratification analyses, which has insufficient statistical power to detect a slight effect or may have generated a fluctuated risk estimate. Moreover, the function and the signaling pathway of *PRKCH* are still largely unknown. Thus, more molecular and cellular experiments should be designed to further illuminate the mechanism involved.

In conclusion, our study showed that the *PRKCH* 1425G/A polymorphism was an independent predictor of ischemic stroke recurrence in a Chinese population. Large well-designed studies with diverse populations and functional evaluations of PKC $\eta$  are warranted to confirm and extend our findings.

**Acknowledgments** This work was supported by National Natural Science Foundation of China (31200938, 81220108008); Natural Science Foundation of Jiangsu Province (BK2011021); and Natural Science Foundation of Jinling Hospital (2012009). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors thank Benjamin L. Kidder (Systems Biology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA) for critical review and language editing of the manuscript.

**Conflict of Interests** The authors declare that they have no conflicts of interest.



## References

1. Bonita R, Mendis S, Truelsen T, Bogousslavsky J, Toole J, Yatsu F (2004) The global stroke initiative. *Lancet Neurol* 3:391–393
2. Seshadri S, Beiser A, Pikula A et al (2010) Parental occurrence of stroke and risk of stroke in their children: the Framingham study. *Circulation* 121:1304–1312
3. Meschia JF, Worrall BB, Rich SS (2011) Genetic susceptibility to ischemic stroke. *Nat Rev Neurol* 7:369–378
4. Hirschhorn JN, Daly MJ (2005) Genome-wide association studies for common diseases and complex traits. *Nat Rev Genet* 6:95–108
5. Kubo M, Hata J, Ninomiya T et al (2007) A nonsynonymous SNP in PRKCH (protein kinase C eta) increases the risk of cerebral infarction. *Nat Genet* 39:212–217
6. Chen YC, Chen P, Wu YR et al (2012) Protein kinase Ceta polymorphism and the susceptibilities to intracerebral hemorrhage in the Taiwan population. *Neurosci Lett* 528:170–173
7. Serizawa M, Nabika T, Ochiai Y et al (2008) Association between PRKCH gene polymorphisms and subcortical silent brain infarction. *Atherosclerosis* 199:340–345
8. Wu L, Shen Y, Liu X et al (2009) The 1425G/A SNP in PRKCH is associated with ischemic stroke and cerebral hemorrhage in a Chinese population. *Stroke* 40:2973–2976
9. Liu X, Xu G, Wu W, Zhang R, Yin Q, Zhu W (2006) Subtypes and one-year survival of first-ever stroke in Chinese patients: the Nanjing stroke registry. *Cerebrovasc Dis* 22:130–136
10. Zhang Z, Xu G, Zhu W et al (2014) Chromosome 12p13 variants predict recurrence of ischaemic stroke in a Chinese population. *Eur J Neurol*. doi:10.1111/ene.12508
11. Thomas G, Sinville R, Sutton S et al (2004) Capillary and microelectrophoretic separations of ligase detection reaction products produced from low-abundant point mutations in genomic DNA. *Electrophoresis* 25:1668–1677
12. Nishizuka Y (1995) Protein kinase C and lipid signaling for sustained cellular responses. *FASEB J* 9:484–496
13. Goldstein LB, Adams R, Alberts MJ et al (2006) Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. *Stroke* 37:1583–1633
14. Messner B, Bernhard D (2014) Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. *Arterioscler Thromb Vasc Biol* 34:509–515
15. Wannamethee SG, Lowe GD, Shaper AG, Rumley A, Lennon L, Whincup PH (2005) Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. *Eur Heart J* 26:1765–1773
16. Barua RS, Ambrose JA, Saha DC, Eales-Reynolds LJ (2002) Smoking is associated with altered endothelial-derived fibrinolytic and antithrombotic factors: an in vitro demonstration. *Circulation* 106:905–908
17. Wilhelmsen L, Svardsudd K, Korsan-Bengtson K, Larsson B, Welin L, Tibblin G (1984) Fibrinogen as a risk factor for stroke and myocardial infarction. *N Engl J Med* 311:501–505
18. Newby DE, Wright RA, Labinjoh C et al (1999) Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. *Circulation* 99:1411–1415
19. Renaud S, Blache D, Dumont E, Thevenon C, Wissendanger T (1984) Platelet function after cigarette smoking in relation to nicotine and carbon monoxide. *Clin Pharmacol Ther* 36:389–395
20. Smith JR, Landaw SA (1978) Smokers' polycythemia. *N Engl J Med* 298:6–10